American Heart Journal
Volume 144, Issue 6 , Pages 995-1002 , December 2002

Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)

Received 11 January 2002 ,Accepted 25 April 2002.

References 

  1. Theroux P, Ouimet H, McCans J, et al.  Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111
  2. The RISC Group . Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830
  3. Holdright D, Patel D, Cunningham D, et al.  Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 1994;24:39–45
  4. Oler A, Whooley MA, Oler J, et al.  Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA. 1996;276:811–815
  5. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. American Heart Association Circulation. 1994;89:1449–1468
  6. Theroux P, Waters D, Lam J, et al.  Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141–145
  7. Barrowcliffe T, Johnson E, Thomas D. Low molecular weight heparin. Chicester (United Kingdom): John Wiley & Sons; 1992;
  8. Bounameaux H. Low molecular weight heparins in prophylaxix and therapy of thromboembolic disease. New York (NY): : Marcel Dekker; 1994;
  9. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688–698
  10. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIB/IIIa inhibitor), heparin, or both in unstable angina . The PARAGON A Investigators. Circulation. 1998;97:2386–2395
  11. Moliterno DJ, Harrington RA, Califf RM, et al.  Randomized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: The PARADIGM study. J Thromb Thrombolysis. 1995;2:165–169
  12. Kong DF, Califf RM, Miller DP, et al.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIB/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829–2835
  13. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators . Inhibition of the platelet glycoprotein IIB/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488–1497
  14. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998;97:1195–1206
  15. Kleiman NS, Lincoff AM, Flaker GC, et al.  Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation. 2000;101:751–757
  16. Cohen M, Demers C, Gurfinkel EP, et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447–452
  17. Moliterno DJ. Patient-specific dosing of IIB/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. Am Heart J. 2000;139:563–566
  18. Antman EM, McCabe CH, Gurfinkel EP, et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601
  19. Boersma E, Pieper KS, Steyerberg EW, et al.  Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000;101:2557–2567
  20. Newby LK, Ohman EM, Christenson RH, et al.  Benefit of glycoprotein IIB/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation. 2001;103:2891–2896
  21. Stricker H, Marchetti O, Haeberli A, et al.  Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin versus nadroparin in the treatment of proximal deep vein thrombosis. Thromb Haemost. 1999;82:1227–1231
  22. Abildgaard U, Lindahl AK, Sandset PM. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis. 1991;21:254–257
  23. Montalescot G, Philippe F, Ankri A, et al.  Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation. 1998;98:294–299
  24. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation. 1998;98:287–289
  25. Antman EM, Cohen M, Radley D, et al.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608
  26. Eikelboom JW, Anand SS, Malmberg K, et al.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942
  27. Kereiakes DJ, Fry E, Matthai W, et al.  Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: “NICE guys finish first.”. J Invasive Cardiol. 2000;12(A Suppl):1A–5A
  28. White HD. Low-molecular-weight heparin and platelet glycoprotein IIB/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?. J Invasive Cardiol. 2000;12(A Suppl):6A–13A
  29. Ferguson J. NICE-3 (National Investigators Collaborating on Enoxaparin-3): prospective, open label, non-randomised observational safety study on the combination of LMW heparin with the clinically available IIB/IIIa antagonists in 600 patients with acute coronary syndromes. Presented at: Proceedings of the 22nd Congress of the European Society of Cardiology; August 26-30, 2000; Amsterdam.
  30. Cohen M, Theroux P, Weber S, et al.  Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol. 1999;71:273–281
  31. Cohen M. ACUTE II: first randomized data on IIB/IIIa blockers and LMW heparin in ACS. Presented at: Proceedings of the American Heart Association Scientific Sessions; November 12-15, 2000; New Orleans.
  32. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study . Fragmin and Fast Revascularisation during InStability in Coronary artery disease. Lancet. 1999;354:701–707
  33. Gulba D. Differentiation of low molecular weight heparins in acute coronary syndromes: an interventionalist's perspective. Semin Thromb Hemost. 1999;25:123–127
  34. Blazing MA, De Lemos JA, Dyke CK, et al.  The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIB/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J. 2001;142:211–217
  35. Cohen M, Maritz F, Gensini GF, et al.  The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design. J Thromb Thrombolysis. 2000;10:241–246

☆ Supported by Hoffman-LA Roche Ltd.

☆☆ Guest Editor for this manuscript was Richard C. Becker, MD, University of Massachusetts Medical Center, Worcester, Mass.

★ Reprint requests: Eric J. Topol, MD, FACC, Chairman, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, F 25, 9500 Euclid Ave, Cleveland, OH 44195.

★★ E-mail: topole@ccf.org

PII: S0002-8703(02)00223-5

doi: 10.1067/mhj.2002.126118

American Heart Journal
Volume 144, Issue 6 , Pages 995-1002 , December 2002

Article Tools

* Image Usage & Resolution